Fosamax vs Prolia (Denosumab): Long-Term Durability of Response

How Each Drug Works and Why Mechanism Shapes Durability

The mechanism difference between these two drugs is not merely pharmacological trivia. It directly determines what happens to your skeleton three, five, or ten years into treatment and what happens the moment you stop.

Alendronate binds permanently to hydroxyapatite crystals in bone matrix. Osteoclasts ingest the drug when they resorb bone and are subsequently disabled. Because the drug is physically embedded in bone, its anti-resorptive effect outlasts any single dose by years. After a 10-year course, measurable alendronate can still be detected in bone tissue, providing residual protection even during a drug holiday.

Denosumab works differently. It is a monoclonal antibody that binds and neutralizes RANK-L, the cytokine that triggers osteoclast formation. No RANK-L signal means far fewer osteoclasts and dramatically reduced bone resorption. The effect is potent. When the antibody clears (roughly 6 months after each injection), osteoclast activity rebounds to above-baseline levels, a phenomenon sometimes called the "rebound resorption" effect.

The Permanence of Bisphosphonate Binding

Alendronate's half-life in bone exceeds 10 years. A 2018 analysis in the Journal of Bone and Mineral Research confirmed that bisphosphonate residues remain pharmacologically active in trabecular bone long after oral dosing stops. This storage depot is why a 1-to-2-year drug holiday is considered safe for many patients after 5 years of alendronate therapy.

Why Denosumab Has No Depot Effect

Denosumab is a biologic with no affinity for bone mineral. Once the antibody degrades, the RANK-L pathway reactivates fully. Bone turnover markers (specifically serum CTX and P1NP) return to pretreatment levels within 3-6 months of a missed injection, and in some patients, they overshoot baseline. That overshoot translates to clinical risk.

Fracture Efficacy: What the Major Trials Show

FIT: Alendronate's Three-Year Evidence

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027 women with low femoral neck BMD) remains the foundational dataset for alendronate [1]. Over 3 years, alendronate 10 mg/day reduced morphometric vertebral fractures by 47% compared to placebo (relative risk 0.53; 95% CI 0.41-0.68; P<0.001). Hip fractures fell by 51% in the subset with existing vertebral fracture. Lumbar spine BMD rose 8.8% from baseline.

FREEDOM: Denosumab's Three-Year Evidence

The FREEDOM trial (NEJM 2009, N=7,808 postmenopausal women aged 60-90) assigned participants to denosumab 60 mg SC every 6 months or placebo for 36 months [2]. New vertebral fractures fell by 68% (RR 0.32; 95% CI 0.26-0.41; P<0.001). Hip fractures fell by 40% and nonvertebral fractures by 20%. Lumbar spine BMD increased 9.2% from baseline. On a head-to-head comparison of these trial designs, denosumab produced numerically larger BMD gains and a higher relative risk reduction for vertebral fracture, though direct randomized comparisons between the drugs are limited.

Direct Comparison Evidence

The DECIDE trial (N=504) and the STAND trial (N=504) each ran for 12 months and compared alendronate directly against denosumab in postmenopausal women [see [3] and [4]]. In DECIDE, denosumab produced significantly greater total hip BMD gains than alendronate (3.5% vs 2.6%, P<0.0001). In STAND, patients switched from alendronate to denosumab gained more hip BMD than those continuing alendronate (1.90% vs 1.05%, P<0.0001). Neither trial was powered for fracture endpoints, so fracture-to-fracture comparisons remain indirect.

Long-Term Durability: Extension Trial Data

Alendronate: FLEX at 10 Years

The Fracture Intervention Trial Long-Term Extension (FLEX) enrolled 1,099 women who had completed 5 years of alendronate and randomized them to continue for 5 more years or switch to placebo [5]. Women continuing alendronate for 10 years maintained slightly higher BMD than those who stopped, but the difference was modest. Nonvertebral fracture rates did not differ significantly between the 10-year and 5-year groups. The investigators concluded that a drug holiday after 5 years is reasonable for women at lower fracture risk, specifically those with a T-score above -2.5 at the femoral neck. Women at higher risk (T-score below -2.5 or prior vertebral fracture) may benefit from continuing beyond 5 years.

Denosumab: FREEDOM Extension at 10 Years

Participants in the original FREEDOM trial who continued denosumab for up to 10 years in the open-label extension showed continuous BMD gains without a plateau [6]. Lumbar spine BMD increased 21.7% from baseline and total hip BMD increased 9.2% at 10 years. Fracture rates remained low and stable. The data suggest that denosumab does not exhibit the diminishing returns seen with some bisphosphonates over very long periods. However, these are extension participants who chose to continue, introducing a healthy-survivor bias that limits interpretation.

The Discontinuation Problem: Rebound Fracture Risk

This is the most clinically significant durability difference between the two drugs. Stopping alendronate is generally safe. Stopping denosumab without a transition plan is not.

Alendronate: Safe to Stop (With Caveats)

After 5 years of alendronate, a drug holiday of 1-3 years is supported by FLEX data [5]. BMD declines slowly and bone turnover markers rise gradually, giving clinicians a reasonable window to monitor and re-evaluate. The American Association of Clinical Endocrinology (AACE) 2020 guidelines state: "After 5 years of oral bisphosphonate therapy in lower-risk patients, a drug holiday of 1-2 years is reasonable, with reassessment of fracture risk at that time" [7].

Denosumab: Rebound Resorption and Multiple Vertebral Fractures

Stopping denosumab without a bridging bisphosphonate is associated with a documented risk of multiple vertebral fractures (MVF). A 2017 analysis in Osteoporosis International identified 13 cases of MVF occurring within 7-24 months of denosumab discontinuation, with an incidence far exceeding background rates [8]. A 2019 systematic review in JAMA Internal Medicine found that approximately 3.4% of patients who discontinued denosumab experienced clinical vertebral fractures within 12 months [9].

The Endocrine Society's 2019 clinical practice guideline states: "After discontinuing denosumab, antiresorptive therapy (preferably a bisphosphonate) should be started to prevent rapid bone loss and potential rebound fractures" [10].

The practical clinical framework for denosumab discontinuation involves three decision points: confirming the patient's current fracture risk tier, choosing whether zoledronic acid IV or oral alendronate is the transition agent, and timing the bisphosphonate to begin within 4-6 months of the last denosumab injection. Waiting longer than 6 months substantially raises the risk of unchecked rebound resorption.

Transition Timing: A Specific Protocol

For a patient on denosumab who must stop (due to cost, jaw osteonecrosis risk, or planned surgery), the following sequence has clinical support from multiple published protocols:

1. Administer the final denosumab dose as scheduled.
2. Begin alendronate 70 mg weekly starting at month 6 after the last injection, or administer a single dose of zoledronic acid 5 mg IV at month 6.
3. Recheck bone turnover markers (serum CTX) at month 9-12. If CTX remains suppressed, the bisphosphonate is providing adequate bridging.
4. Continue bisphosphonate for at least 12-24 months before reassessing fracture risk.

Switching From Fosamax to Prolia: Who Benefits and How to Do It

Switching from alendronate to denosumab is one of the more commonly requested transitions in osteoporosis management. The data support the switch in specific clinical contexts.

When the Switch Makes Clinical Sense

Patients who may benefit from switching include those with a declining BMD response to alendronate despite adherence, those with GI intolerance to oral bisphosphonates, patients with chronic kidney disease (alendronate is not recommended when eGFR <35 mL/min/1.73m2, while denosumab has no renal dose restriction), and patients with a very high fracture risk (T-score below -3.0 or prior hip fracture) who may benefit from the numerically superior vertebral fracture reduction seen with denosumab in FREEDOM [2].

What the STAND Trial Tells Us About Switching

The STAND trial (N=504) specifically enrolled women already on weekly alendronate for at least 6 months and randomized them to continue alendronate or switch to denosumab 60 mg every 6 months for 12 months [4]. Denosumab-treated women gained significantly more total hip BMD (1.90% vs 1.05%, P<0.0001) and trochanter BMD. Bone turnover markers also fell more in the denosumab group. The switch was well tolerated with no excess adverse events.

When to Avoid the Switch

Patients who are unreliable with appointment adherence should be counseled carefully before starting denosumab. Missing an injection by more than 2-3 months begins to permit rebound resorption. A patient who cannot reliably attend a clinic every 6 months may be safer on a weekly oral alendronate regimen or on an annual IV zoledronic acid infusion.

Safety Profiles Over Time

Alendronate: Atypical Femur Fracture and Osteonecrosis of the Jaw

Long-term alendronate use (beyond 5 years) carries a small but real risk of atypical femur fracture (AFF). An FDA review estimated the absolute risk at approximately 3.2-50 cases per 100,000 person-years, increasing with duration of use [11]. Osteonecrosis of the jaw (ONJ) occurs in fewer than 1 in 10,000 patients on oral bisphosphonates for osteoporosis. These risks should be weighed against sustained fracture protection, not used as reasons to avoid therapy in high-risk patients.

Denosumab: Hypocalcemia, Infections, and ONJ

Denosumab carries a risk of hypocalcemia, particularly in patients with vitamin D deficiency or renal impairment. FREEDOM reported hypocalcemia in 0.05% of denosumab patients vs 0% placebo [2]. Skin infections (cellulitis) occurred at a slightly higher rate in the denosumab group (0.3% vs 0.1%). ONJ risk with denosumab in osteoporosis patients is similarly low (roughly 1 in 10,000) but rises sharply with concomitant cancer treatment doses (120 mg monthly). Renal function does not need to be monitored before each dose for osteoporosis indications, which is a meaningful practical advantage.

Practical Prescribing: Matching Drug to Patient

Not every patient with osteoporosis fits the same profile. Three clinical archetypes illustrate where each drug excels.

The Newly Diagnosed Patient With Moderate Risk

A 65-year-old woman with a T-score of -2.5 at the lumbar spine, no prior fractures, normal renal function, and no GI disease is a reasonable candidate for alendronate 70 mg weekly. She has low absolute risk of AFF, can absorb the drug orally without issue, and if she chooses to stop after 5-7 years, she can do so safely. Starting with denosumab in this profile creates a long-term commitment that may be difficult to exit safely.

The High-Risk Patient With Prior Vertebral Fracture

A 72-year-old woman with a T-score of -3.1, two prior vertebral fractures, and eGFR of 30 mL/min/1.73m2 is a stronger candidate for denosumab. Alendronate is not recommended at this level of renal impairment. Denosumab's 68% vertebral fracture risk reduction in FREEDOM [2] and its continuous BMD gains over 10 years in the extension trial [6] make it appropriate for severe cases. The transition plan on eventual stopping must be discussed at initiation, not as an afterthought years later.

The Patient Requesting a Medication Change

A 68-year-old woman who has taken alendronate for 6 years, has a T-score that has stabilized at -2.2 at the hip, but continues to have new vertebral fractures on imaging, warrants re-evaluation. Switching to denosumab (with STAND data supporting improved BMD response) or escalating to an anabolic agent such as teriparatide or romosozumab may both be appropriate next steps. A discussion with an endocrinologist or metabolic bone specialist is appropriate before continuing the same bisphosphonate in a patient who shows inadequate response.

Cost, Access, and Real-World Adherence

Alendronate is generic and inexpensive. A 3-month supply typically costs less than $20 without insurance in the United States, making adherence barriers primarily behavioral rather than financial.

Denosumab (Prolia) carries a list price above $1,400 per injection in the US, though Medicare Part B and commercial insurance typically cover it with prior authorization for patients meeting T-score or fracture criteria. A biosimilar denosumab (Jubbonti and Wyost, both FDA-approved as of June 2024) may reduce costs significantly once widely adopted [12].

Real-world adherence data for bisphosphonates is poor. A review in Osteoporosis International found that fewer than 50% of patients are still taking oral bisphosphonates at 12 months [13]. Denosumab's twice-yearly injection schedule may improve persistence in some patients, though missed injections carry a safety consequence that missed oral doses do not.

BMD Response Comparison at a Glance

| Outcome | Alendronate (FIT / FLEX) | Denosumab (FREEDOM / Extension) | |---|---|---| | Lumbar spine BMD at 3 years | +8.8% | +9.2% | | Total hip BMD at 3 years | +5.9% | +6.0% | | Vertebral fracture reduction (3 yr) | 47% | 68% | | Hip fracture reduction (3 yr) | 51% | 40% | | BMD at 10 years (continuous use) | Plateau around yr 5-7 | +21.7% LS (no plateau) | | Effect after stopping | Persists 1-5 years | Reverses within 12 months |